NLS Pharmaceutics Announces Positive Opinion from European Regulators to Grant Orphan Drug Designation for Mazindol ER in Idiopathic Hypersomnia
NLS Pharmaceutics Announces Positive Interim Top-Line Data for Quilience® (Mazindol ER) in Patients with Narcolepsy